A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060

← catalyst calendar

NCT07160738

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 1

Status

Completed

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

25actual

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-09-22

actual

When the study began enrolling

Primary completion

2025-11-24

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2025-12-22

actual

The whole study's end, after follow-up

First posted

2025-09-08

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-04-03

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Healthy Adults

Interventions

Drug: PF-07220060
Drug: Itraconazole
Drug: Probenecid

Primary outcomes

what the primary-completion date above is the date OF

Plasma PF-07220060 Maximum Observed Plasma Concentration (Cmax)

measured Pre-dose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 and 120 hours post PF-07220060 dose for Period 1; Pre-dose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 and 144 hours post PF-07220060 dose for Period 2

Plasma PF-07220060 Area under the plasma concentration versus time curve (AUC)

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed